特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒトマイクロバイオーム(ヒト微生物叢)の世界市場:製品(プロバイオティクス、プレバイオティクス、医療食)、疾患、用途、地域別

Global Human Microbiome Market - Analysis By Product (Probiotics, Prebiotics, Medical Food, Others), By Disease, Application, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)

発行 Azoth Analytics 商品コード 923536
出版日 ページ情報 英文 250 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
ヒトマイクロバイオーム(ヒト微生物叢)の世界市場:製品(プロバイオティクス、プレバイオティクス、医療食)、疾患、用途、地域別 Global Human Microbiome Market - Analysis By Product (Probiotics, Prebiotics, Medical Food, Others), By Disease, Application, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)
出版日: 2020年01月31日 ページ情報: 英文 250 Pages
概要

世界のヒトマイクロバイオーム(ヒト微生物叢)市場は、2018年に3億5,181万米ドルと評価されました。ここ数年、ヒトマイクロバイオーム(ヒト微生物叢)市場は、糖尿病の罹患率の上昇や、高齢者人口の増加、製薬メーカーおよび学術機関による継続的な研究開発などによって、大きな成長を目の当たりにしてきました。また、体を動かすことの少ないライフスタイルや、慢性疾患の世界的な増加なども当市場の成長に寄与しています。

当レポートでは、世界のヒトマイクロバイオーム(ヒト微生物叢)市場を調査し、市場の概要、製品・疾患・用途・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法とエグゼクティブサマリー

  • 調査方法
  • エグゼクティブサマリー

第2章 戦略的な推奨事項

第3章 製品の見通し

第4章 市場規模と予測

  • 市場規模:金額ベース(実績値・予測値)

第5章 世界のヒトマイクロバイオーム市場:製品別

  • 競争シナリオ:製品別
  • プロバイオティクス
  • プレバイオティクス
  • 医療食
  • その他

第6章 世界のヒトマイクロバイオーム市場:疾患別

  • 競争シナリオ:疾患別
  • 肥満
  • 糖尿病
  • 自己免疫疾患
  • がん
  • 消化器疾患
  • その他

第7章 世界のヒトマイクロバイオーム市場:用途別

  • 競争シナリオ:用途別
  • 治療薬
  • 診断

第8章 世界のヒトマイクロバイオーム市場:地域別

  • 競争シナリオ:地域別

第9章 北米のヒトマイクロバイオーム市場

  • 北米のヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • 市場区分:製品別
  • 市場区分:疾患別
  • 市場区分:用途別
  • 市場分析:国別
  • 市場機会
  • 競合シナリオ:国別
  • 米国のヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • 米国のヒトマイクロバイオーム市場:セグメント別
  • カナダのヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • カナダのヒトマイクロバイオーム市場:セグメント別

第10章 欧州のヒトマイクロバイオーム市場

  • 欧州のヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • 市場区分:製品別
  • 市場区分:疾患別
  • 市場区分:用途別
  • 市場分析:国別
  • 市場機会
  • 競合シナリオ:国別
  • 英国のヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • 英国のヒトマイクロバイオーム市場:セグメント別
  • ドイツのヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • ドイツのヒトマイクロバイオーム市場:セグメント別
  • フランスのヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • フランスのヒトマイクロバイオーム市場:セグメント別
  • その他の国ののヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • その他の国ののヒトマイクロバイオーム市場:セグメント別

第11章 アジア太平洋地域のヒトマイクロバイオーム市場

  • アジア太平洋地域のヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • 市場区分:製品別
  • 市場区分:疾患別
  • 市場区分:用途別
  • 市場分析:国別
  • 市場機会
  • 競合シナリオ:国別
  • 中国のヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • 中国のヒトマイクロバイオーム市場:セグメント別
  • インドのヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • インドのヒトマイクロバイオーム市場:セグメント別
  • 日本のヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • 日本のヒトマイクロバイオーム市場:セグメント別
  • 韓国のヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • 韓国のヒトマイクロバイオーム市場:セグメント別
  • その他の国ののヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • その他の国ののヒトマイクロバイオーム市場:セグメント別

第12章 その他の地域のヒトマイクロバイオーム市場

  • その他の地域のヒトマイクロバイオーム市場:金額ベース(実績値・予測値)
  • 市場区分:セグメント別

第13章 市場力学

  • 成長要因
  • 阻害要因
  • 市場動向

第14章 市場魅力分析

  • 市場魅力分析:製品別
  • 市場魅力分析:疾患別
  • 市場魅力分析:用途別
  • 市場魅力分析:地域別

第15章 競合情勢

  • 大手製薬企業とバイオテクノロジー企業のライセンス取引
  • 市場シェア分析
  • SWOT分析
  • ファイブフォース分析

第16章 企業プロファイル

  • OptiBiotix Health Plc
  • Metabiomics
  • OSEL Inc.
  • PureTech Health
  • 4D Pharma
  • Synlogic Inc.
  • BaseClear BV
  • Rebiotix Inc
  • Ritter Pharmaceuticals
  • Assembly Bioscience Inc.
図表

List of Figures

  • Figure 1: Global Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 2: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
  • Figure 3: Number of New Cases of Cancer, In 2018, By Region, (% of Total)
  • Figure 4: Number of New Cases of Cancer, 2018, By Type, (% of Total)
  • Figure 5: Global Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
  • Figure 6: Global Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 7: Prevalence of Diagnosed Autoimmune Diseases, In 2018, By Selected Countries, (% of Total)
  • Figure 8: Prevalence of diagnosed gastrointestinal conditions, By Select Countries, 2017 (In %)
  • Figure 9: Global Aged Population (Above 65), 2013-2017 (% of total)
  • Figure 10: Global Aged Population(Above 65), By Country, 2017 (% of total)
  • Figure 11: Number of microbiome modulators in active development, by year, 2012-17
  • Figure 12: Global Microbiome, No. of active drugs in market
  • Figure 13: Obese Population, By Country, 2017 (In Millions)
  • Figure 14: Inner Pie: Segmental Analysis By Product: Year 2018, Outer Pie: Segmental Analysis By Product: Year 2024
  • Figure 15: Global Human Microbiome Market- By Probiotic, By Value (USD Million), 2014-2024
  • Figure 16: Global Human Microbiome Market- By Prebiotic, By Value (USD Million), 2014-2024
  • Figure 17: Global Human Microbiome Market- By Medical Food, By Value (USD Million), 2014-2024
  • Figure 18: Global Human Microbiome Market- By Others, By Value (USD Million), 2014-2024
  • Figure 19: Inner Pie: Segmental Analysis By Disease: Year 2018, Outer Pie: Segmental Analysis By Disease: Year 2024
  • Figure 20: Global Human Microbiome Market- By Obesity, By Value (USD Million), 2014-2024
  • Figure 21: Inner Global Human Microbiome Market- By Diabetes Type II, By Value (USD Million), 2014-2024
  • Figure 22: Global Human Microbiome Market- By Autoimmune Disorder, By Value (USD Million), 2014-2024
  • Figure 23: Global Human Microbiome Market- By Cancer, By Value (USD Million), 2014-2024
  • Figure 24: Global Human Microbiome Market- By Gastrointestinal Disorder, By Value (USD Million), 2014-2024
  • Figure 25: Global Human Microbiome Market- By Others, By Value (USD Million), 2014-2024
  • Figure 26: Inner Pie: Segmental Analysis By Application: Year 2018, Outer Pie: Segmental Analysis By Application: Year 2024
  • Figure 27: Global Human Microbiome Market- By Therapeutic, By Value (USD Million), 2014-2024
  • Figure 28: Global Human Microbiome Market- By Diagnostics, By Value (USD Million), 2014-2024
  • Figure 29: Global Market Scenario, By Region (USD Million)
  • Figure 30: Inner Pie: Segmental Analysis By Region: Year 2018, Outer Pie: Segmental Analysis By Region: Year 2024
  • Figure 31: North America Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 32: United States health care expenditure per capita,2013-2016(USD)
  • Figure 33: Canada health care expenditure per capita,2013-2016(USD)
  • Figure 34: North America Healthcare Cost Per Capita, 2017 (USD)
  • Figure 35: North America population aged 65 and above, 2013-2017 (% of total)
  • Figure 36: North America Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
  • Figure 37: North America Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 38: North America Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 39: North America Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 40: North America Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 41: Market Opportunity Chart of North America Human Microbiome Market - By Country, By Value (Year-2024)
  • Figure 42: Inner Pie: Segmental Analysis By Country: Year 2018, Outer Pie: Segmental Analysis By Country: Year 2024
  • Figure 43: United States Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 44: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
  • Figure 45: U.S., Population ages 65 and above, 2013-2017 (% of total)
  • Figure 46: U.S., Percentage of IBD patients that received select treatments as of 2017 (in %)
  • Figure 47: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)
  • Figure 48: United States Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
  • Figure 49: United States Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 50: United States Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 51: United States Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 52: United States Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 53: Canada Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 54: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
  • Figure 55: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
  • Figure 56: Canada, Population ages 65 and above, 2012-2017 (% of total)
  • Figure 57: Canada Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
  • Figure 58: Canada Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 59: Prevalence of Diabetics in Canada, (% of Total Population) 2015 & 2045E
  • Figure 60: Estimated Prevalence of Pre-Diabetics in Canada, (% of Total Population) 2015 & 2045E
  • Figure 61: Overweight and Obese Population in Canada, 2015-2017 (% of total)
  • Figure 62: Canada Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 63: Canada Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 64: Canada Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 65: Mexico Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 66: Mexico Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
  • Figure 67: Mexico Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 68: Mexico Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 69: Mexico Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 70: Mexico Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 71: Europe Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 72: European Country Population Aged 65 and Above, 2012-2017 (% of Total)
  • Figure 73: European Union, Population ages 65 and above, 2013-2017 (% of total)
  • Figure 74: Prevalence of Diabetes (Age 18+), 2017 & 2045E (In Million)
  • Figure 75: Diabetes Prevalence (% of population ages 20 to 79), By Select Country, 2017
  • Figure 76: Europe Health Expenditure, By Select Country, 2016 (% of GDP)
  • Figure 77: Europe Population ages 65 years and above (% of total population), 2013-17
  • Figure 78: Europe Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
  • Figure 79: Europe Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 80: Per Capita Health Expenditure, By Select Country, 2017 (USD)
  • Figure 81: Europe Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 82: Europe Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 83: Europe Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 84: Market Opportunity Chart of Human Microbiome Market - By Country, By Value (Year-2024)
  • Figure 85: Inner Pie: Segmental Analysis By Country: Year 2018, Outer Pie: Segmental Analysis By Country: Year 2024
  • Figure 86: United Kingdom Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 87: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)
  • Figure 88: U.K, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 89: UK, Prevalence of Cancer, 2018, (% of Total)
  • Figure 90: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 91: U.K, Cause of Death, Percentage Change Between 2007-2017
  • Figure 92: United Kingdom Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
  • Figure 93: United Kingdom Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 94: United Kingdom Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 95: United Kingdom Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 96: United Kingdom Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 97: Germany Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 98: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
  • Figure 99: Germany, Population ages 65 and above, 2012-2017 (% total)
  • Figure 100: Germany Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
  • Figure 101: Germany Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 102: Germany Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 103: Germany Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 104: Germany Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 105: France Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 106: France, Health Expenditure, (% of GDP), 2012-2015 (USD)
  • Figure 107: France, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 108: France, Spending on Healthcare, 2015 & 2040$, (USD Per Person)
  • Figure 109: France Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
  • Figure 110: France Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 111: France Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 112: France Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 113: France Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 114: Rest of The Europe Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 115: Rest of The Europe Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 116: Rest of The Europe Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 117: Rest of The Europe Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 118: APAC Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 119: Population ages 65 and above, APAC Region, By Select Countries, 2017 (% of total)
  • Figure 120: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
  • Figure 121: Diabetes Prevalence (% of population ages 20 to 79), By Selected Country, 2017
  • Figure 122: Obesity Rate, By Selected Country, 2017 (In Percentage)
  • Figure 123: Asia Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
  • Figure 124: Asia Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 125: Obesity Rate, By Select Country, 2017 (In Percentage)
  • Figure 126: APAC Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 127: APAC Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 128: APAC Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 129: Market Opportunity Chart of APAC Human Microbiome Market - By Country, By Value (Year-2024)
  • Figure 130: Inner Pie: Segmental Analysis By Country: Year 2018, Outer Pie: Segmental Analysis By Country: Year 2024
  • Figure 131: China Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 132: China, Population Ages 65 and Above, 2012-2017 (% of total)
  • Figure 133: China, Cancer Incidences ( in Million)
  • Figure 134: China Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Millions)
  • Figure 135: China Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 136: China Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 137: China Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 138: China Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 139: India Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 140: India, Population Ages 65 and Above, 2013-2017
  • Figure 141: India Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
  • Figure 142: India Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 143: India, Diseases Outlook & India, Medical Industry Outlook
  • Figure 144: India Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 145: India Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 146: India Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 147: Japan Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 148: Japan, GDP Growth Per Year, 2015-2019F (In %)
  • Figure 149: Japan Healthcare Expenditure Outlook (%)
  • Figure 150: Japan, Population ages 65 and above, 2012-2016 (% of total)
  • Figure 151: Japan Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
  • Figure 152: Japan Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 153: Japan Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 154: Japan Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 155: Japan Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 156: South Korea Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 157: South Korea Prevalence of Inflammatory Bowel Disease, 2014-2017 (In Thousands)
  • Figure 158: South Korea Prevalence of Diabetes Type II, 2014-2017 (In Millions)
  • Figure 159: South Korea Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 160: South Korea Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 161: South Korea Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 162: Rest of the APAC Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 163: Rest of the APAC Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 164: Rest of the APAC Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 165: Rest of the APAC Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 166: Rest of the World Human Microbiome Market Size, By Value, 2014-2024 (USD Million)
  • Figure 167: Latin America and Caribbean, Population ages 65 and above (% of total)
  • Figure 168: Middle East and North Africa, Population ages 65 and above (% of total)
  • Figure 169: Cancer Prevalence in Latin America & Caribbean , (% of total), 2018
  • Figure 170: Population ages 65 and above, By Select Country, 2018 (% of total)
  • Figure 171: Population ages 60 or above, By Select Country, 2050 (% of total)
  • Figure 172: ROW Human Microbiome Market- By Products, By Value (USD Million), 2014-2024
  • Figure 173: ROW Human Microbiome Market- By Disease, By Value (USD Million), 2014-2024
  • Figure 174: ROW Human Microbiome- By Application, By Value (USD Million), 2014-2024
  • Figure 175: Market Attractiveness Chart of Global Human Microbiome Market - By Products (Year-2024)
  • Figure 176: Market Attractiveness Chart of Global Human Microbiome Market - By Disease (Year-2024)
  • Figure 177: Market Attractiveness Chart of Global Human Microbiome Market - By Application (Year-2024)
  • Figure 178: Market Attractiveness Chart of Global Human Microbiome Market - By Region, By Value, (Year-2024)
  • Figure 179: OptiBiotix Health Plc Annual Revenue (USD Th.), Year 2015-2018
  • Figure 180: OptiBiotix Health Plc Net Profit/Loss (USD Th.), Year 2014-2018
  • Figure 181: PureTech Health Annual Revenue (USD Million), Year 2014-2018
  • Figure 182: PureTech Health Net Profit/Loss (USD Million), Year 2014-2018
  • Figure 183: 4D Pharma Investment in R&D (USD Th.), 2014-2018
  • Figure 184: 4D Pharma Net Loss (USD Th.) 2014-2018
  • Figure 185: Synlogic Inc. Investment in R&D (USD Th.), 2014-2018
  • Figure 186: Synlogic Inc. Net Loss (USD Th.) 2014-2018
  • Figure 187: Synlogic Inc. Revenue (USD Th.), 2017-2018
  • Figure 188: Ritter Pharmaceuticals Investment in R&D (USD Th.) 2014-2018
  • Figure 189: Ritter Pharmaceuticals Net Loss (USD Th.) 2014-2018
  • Figure 190: Assembly Bioscience Inc. Investment in R&D (USD Th.) 2014-2018
  • Figure 191: Assembly Bioscience Inc. Net Loss (USD Th.) 2014-2018

List Of Table

  • Table A: Association of the Gut Microbiome with Therapeutic Effects of Drugs
  • Table B: Prominent Human Microbiome companies operated in Americas Market
  • Table C: Prominent Human Microbiome companies operated in Europe Market
  • Table D: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10)
  • Table E: List Of Pipeline Products
  • Table F: Microbiome Licensing Deals Between Big Pharma & Biotech (2014-2019)
目次

Executive Summary:

The Human Microbiome market was valued at USD 351.81 million in the year 2018. Over the recent years, human microbiome market has been witnessing considerable growth on the back of rising incidences of diabetes, growing geriatric population, and continuous research and development conducted by pharmaceutical manufacturers and academia. In addition, growing sedentary lifestyle, increasing incidence of diabetes and chronic diseases globally have contributed to the growth rate of Human Microbiome market. These factors are anticipated to provide higher momentum to the market growth in the forecast period. Further, the increasing collaboration in the industry between market players and academia to generate data and treatment for the diseases including gut related problems which can be tackled with the help of microbiota, facilitating the growth of the market.

Among the Product type in the human microbiome industry (probiotics, prebiotics, medical foods, and other), Probiotics holds the highest market share in the Human Microbiome Market owing to its proven benefits in gut microbiota and health of the patient.

The North America Human Microbiome Market will continue to be the largest market throughout the forecast period, majorly driven by favourable government reimbursement policies in addition to high healthcare awareness. Countries such as India, China, Brazil are a lucrative market for Human Microbiome Market.

Scope of the Report:

  • The report analyses the Human Microbiome market at global, regional and country levels.
  • The report analyses the Human Microbiome Market by Product (Probiotics, Prebiotics, Medical Food and Others).
  • The report assesses the Human Microbiome market by Disease (Obesity, Diabetes, Cancer, Autoimmune Disorder, Gastrointestinal Disorder and Others).
  • The report evaluates the Human Microbiome market By Application (Therapeutic and Diagnostics).
  • The Global Human Microbiome Market has been analysed By Region (North America, Europe, Asia Pacific, ROW) and By Country (U.S., Canada, Mexico, U.K., Germany, France, India, China, Japan, South Korea).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by product, disease and application. Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include OptiBiotix Health Plc, Metabiomics, OSEL Inc., PureTech Health, 4D Pharma, Synlogic Inc., BaseClear BV, Rebiotix Inc, Ritter Pharmaceuticals, Assembly Bioscience Inc.
  • The report presents the analysis of human microbiome market for the historical period of 2014-2018 and the forecast period of 2019-2024.

Key Target Audience:

  • Food and Beverage Companies
  • Human Microbiome Vendors
  • Consulting and Advisory Firms
  • Government and Policy Makers
  • Investment Banks and Equity Firms
  • Regulatory Authorities

Table of Contents

1. Report scope & Methodology

  • 1.1 Scope of the Report
  • 1.2 Research Methodology
  • 1.3 Executive Summary

2. Strategic Recommendations

  • 2.1 APAC region to witness augmented growth in the forecast period.
  • 2.2 Invest in Research and Development activities

3. Global Human Microbiome Market: Product Outlook

4. Global Human Microbiome Market: Sizing and Forecast

  • 4.1 Market Size, By Value, Year 2014-2024

5. Global Human Microbiome Market Segmentation By Product

  • 5.1 Competitive Scenario of Global Human Microbiome Market - By Product
  • 5.2 Probiotics - Market Size and Forecast (2019-2024)
  • 5.3 Prebiotics - Market Size and Forecast (2019-2024)
  • 5.4 Medical Foods - Market Size and Forecast (2019-2024)
  • 5.5 Others - Market Size and Forecast (2019-2024)

6. Global Human Microbiome Market Segmentation By Disease

  • 6.1 Competitive Scenario of Global Human Microbiome - By Disease
  • 6.2 Obesity - Market Size and Forecast (2019-2024)
  • 6.3 Diabetes Type II - Market Size and Forecast (2019-2024)
  • 6.4 Autoimmune Disorder - Market Size and Forecast (2019-2024)
  • 6.5 Cancer - Market Size and Forecast (2019-2024)
  • 6.6 Gastrointestinal Disorder - Market Size and Forecast (2019-2024)
  • 6.7 Others - Market Size and Forecast (2019-2024)

7. Global Human Microbiome Market Segmentation By Application

  • 7.1 Competitive Scenario of Global Human Microbiome: By Application
  • 7.2 Therapeutics - Market Size and Forecast (2019-2024)
  • 7.3 Diagnostics - Market Size and Forecast (2019-2024)

8. Global Human Microbiome Market: Regional Analysis

  • 8.1 Competitive Scenario of Global Human Microbiome: By Region

9. North America Human Microbiome Market: Segmentation By Products, Disease, Application (2019-2024)

  • 9.1 North America Human Microbiome Market: Size and Forecast (2019-2024)
  • 9.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other)
  • 9.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others)
  • 9.4 Market Segmentation By Application (Therapeutics & Diagnostics)
  • 9.5 North America Human Microbiome Market: Country Analysis
  • 9.6 Market Opportunity Chart of North America Human Microbiome Market - By Country, By Value (Year-2024)
  • 9.7 Competitive Scenario of North America Human Microbiome: By Country
  • 9.8 United States Human Microbiome Market: Size and Forecast (2019-2024)
  • 9.9 United States Human Microbiome Market Segmentation By Product, Disease, Application
  • 9.10 Canada Human Microbiome Market: Size and Forecast (2019-2024)
  • 9.11 Canada Human Microbiome Market Segmentation By Product, Disease, Application
  • 9.12 Mexico Human Microbiome Market: Size and Forecast (2019-2024)
  • 9.13 Mexico Human Microbiome Market Segmentation By Products, Disease, Application

10. Europe Human Microbiome Market: Segmentation By Product, Disease, Application (2019-2024)

  • 10.1 Europe Human Microbiome Market: Size and Forecast (2019-2024)
  • 10.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other)
  • 10.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others)
  • 10.4 Market Segmentation By Application (Therapeutics & Diagnostics)
  • 10.5 Europe Human Microbiome Market: Country Analysis
  • 10.6 Market Opportunity Chart of Europe Human Microbiome Market - By Country, By Value (Year-2024)
  • 10.7 Competitive Scenario of Europe Human Microbiome: By Country
  • 10.8 United Kingdom Human Microbiome Market: Size and Forecast (2019-2024)
  • 10.9 United Kingdom Human Microbiome Market Segmentation By Product, Disease, Application
  • 10.10 Germany Human Microbiome Market: Size and Forecast (2019-2024)
  • 10.11 Germany Human Microbiome Market Segmentation By Product, Disease, Application
  • 10.12 France Human Microbiome Market: Size and Forecast (2019-2024)
  • 10.13 France Human Microbiome Market Segmentation By Products, Disease, Application
  • 10.14 Rest of the Europe Human Microbiome Market: Size and Forecast (2019-2024)
  • 10.15 Rest of the Europe Human Microbiome Market Segmentation By Products, Disease, Application

11. Asia Pacific Human Microbiome Market: Segmentation By Products, Disease, Application (2019-2024)

  • 11.1 Asia Pacific Human Microbiome Market: Size and Forecast (2019-2024)
  • 11.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other)
  • 11.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others)
  • 11.4 Market Segmentation By Application (Therapeutics & Diagnostics)
  • 11.5 Asia Pacific Human Microbiome Market: Country Analysis
  • 11.6 Market Opportunity Chart of Asia Pacific Human Microbiome Market - By Country, By Value (Year-2024)
  • 11.7 Competitive Scenario of Asia Pacific Human Microbiome: By Country
  • 11.8 China Human Microbiome Market: Size and Forecast (2019-2024)
  • 11.9 China Human Microbiome Market Segmentation By Product, Disease, Application
  • 11.10 India Human Microbiome Market: Size and Forecast (2019-2024)
  • 11.11 India Human Microbiome Market Segmentation By Product, Disease, Application
  • 11.12 Japan Human Microbiome Market: Size and Forecast (2019-2024)
  • 11.13 Japan Human Microbiome Market Segmentation By Products, Disease, Application
  • 11.14 South Korea Human Microbiome Market: Size and Forecast (2019-2024)
  • 11.15 South Korea Human Microbiome Market Segmentation By Products, Disease, Application
  • 11.16 Rest of the Asia Pacific Human Microbiome Market: Size and Forecast (2019-2024)
  • 11.17 Rest of the Asia Pacific Human Microbiome Market Segmentation By Products, Disease, Application

12. Rest of the World Human Microbiome Market: Segmentation By Products, Disease, Application (2019-2024)

  • 12.1 Rest of the World Human Microbiome Market: Size and Forecast (2019-2024)
  • 12.2 Market Segmentation By Products (Probiotics, Prebiotics, Medical Food & Other)
  • 12.3 Market Segmentation By Disease (Obesity, Diabetes Type-II, Autoimmune Disorder, Cancer, Gastrointestinal Disorder & Others)
  • 12.4 Market Segmentation By Application (Therapeutics & Diagnostics)

13. Global Human Microbiome Market Dynamics

  • 13.1 Global Human Microbiome Market Drivers
  • 13.2 Global Human Microbiome Market Restraints
  • 13.3 Global Human Microbiome Market Trends

14. Market Attractiveness and Strategic Analysis

  • 14.1 Market Attractiveness
    • 14.1.1 Market Attractiveness Chart of Global Human Microbiome Market - By Products (Year 2024)
    • 14.1.2 Market Attractiveness Chart of Global Human Microbiome Market - By Disease (Year 2024)
    • 14.1.3 Market Attractiveness Chart of Global Human Microbiome Market - By Application (Year-2024)
    • 14.1.4 Market Attractiveness Chart of Global Human Microbiome Market - By Region, By Value, (Year-2024)
  • 14.2 Strategic Analysis
    • 14.2.1 Key Developments in Human Microbiome Market
    • 14.2.3 Human Microbiome Pipeline Projects

15. Competitive Landscape

  • 15.1 Microbiome Licensing Deals Between Big Pharma and Biotech
  • 15.2 Market Share Analysis
  • 15.3 SWOT Analysis
  • 15.4 Porter's Five Force Analysis

16. Company Profiles (Business Description, Financial Analysis, Business Strategy)

  • 16.1 OptiBiotix Health Plc
  • 16.2 Metabiomics
  • 16.3 OSEL Inc.
  • 16.4 PureTech Health
  • 16.5 4D Pharma
  • 16.6 Synlogic Inc.
  • 16.7 BaseClear BV
  • 16.8 Rebiotix Inc
  • 16.9 Ritter Pharmaceuticals
  • 16.10 Assembly Bioscience Inc.